New Clinical Trial Focused on Relapse Prevention in Patients with Acute Myeloid Leukemia Undergoing Bone Marrow Transplant
Investigator-Initiated Trial; Only Available at Siteman Cancer Center, Siteman Kids in St. Louis ST. LOUIS — A new and promising clinical trial aimed at preventing relapse in patients diagnosed with acute myeloid leukemia (AML) is now open at Washington University School of Medicine in St. Louis. The trial (NCT06158828) is only available to […]
New Clinical Trials Open for Sarcomas and Solid Tumors
Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and solid tumors. For BRAF B600 […]
Whole Genome Sequencing for AML/MDS Risk Stratification
ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials are utilizing a breakthrough whole-genome […]
Siteman Cancer Center Advances Head and Neck Tumor Discovery
Soon, a global, stage III randomized clinical trial could result in a paradigm shift in how certain head and neck cancers are treated. The clinical trial, called KEYNOTE-689 and overseen by the Merck pharmaceutical company, is the result of specific research initiated by head and neck cancer specialists at Siteman Cancer Center at Barnes-Jewish Hospital […]
Washington University School of Medicine in St. Louis Awarded $10.9 Million SPORE Grant for Pancreas Cancer
New Clinical Trials Set for Pancreatic Ductal Adenocarcinoma Clinical researchers at Washington University School of Medicine in St. Louis have been awarded a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Awarded in July 2023, it marks the […]
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can control the disease for extended […]
New Clinical Trials for Prostate, Kidney Cancers
Siteman Cancer Center has three new clinical trials open focused on prostate and kidney cancers. The first, a Phase II clinical trial testing a neoadjuvant immunotherapy treatment for prostate cancer, is available for men who have been diagnosed with localized prostate cancer. The study will evaluate the use of atezolizumab alone and in combination with […]
Early Phase Clinical Trial Focuses on Reducing Tumor Growth and Bone Loss in Patients with Breast Cancer and Bone Metastasis
Beginning next year, Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital will initiate a new early phase clinical trial aimed at stopping bone loss and cancer progression in patients with metastatic breast cancer (MBC). The trial is based on promising laboratory research conducted at the School of Medicine that showed a […]
Novel Lymphoma Clinical Trials Underway
In just the past five years, the development of new therapeutics has changed the paradigm for the treatment of lymphomas, thereby improving outcomes and quality of life. As research continues, a major goal is to find more tolerable treatment options with higher efficacy. At Siteman Cancer Center, 35 open clinical trials are investigating novel immunotherapies, […]
Investigating New Treatment Options – New Clinical Trial: First Personalized Vaccine for Small Cell Lung Cancer
At Siteman Cancer Center, a new clinical trial is underway that will evaluate the benefits of a neoantigen vaccine in combination with chemotherapy and immunotherapy to treat small cell lung cancer (SCLC). The rapidly growing, aggressive cancer represents about 15% of all lung cancers in the U.S. SCLC has low survival rates, with most cases […]